In the USA, the combination can be used on adults and children over 12 years old, including the elderly and people with chronic medical conditions
Anvisa / AscomNow, Anvisa will sort the documents in 72 hours and will have up to 30 days to evaluate the request.
A National Health Surveillance Agency received a request for joint emergency use of medicines casiri-vimabe e unde-vimabe for treatment of Covid-19. The order was placed on Friday, 2, by the pharmaceutical company Roche – which delivered 3,626 pages of data and information for analysis. Now, Anvisa will sort the documents in 72 hours and will have up to 30 days to evaluate the request.
Infectologist Renato Kfouri explains that the combination of medicines serves to try to neutralize some parts of the virus and prevent it from evolving. “It is not yet a highly defined product, its effectiveness with licensing in many countries, nor of indiscriminate use. It is reserved for some moments of the disease, in the beginning, for patients at risk who are more likely to evolve seriously. Unfortunately, it is still a very expensive therapy. ”
In the assessment, Anvisa will use the report from the American health authority, FDA, which authorized the use of Covid-19 mild and moderate medications in November 2020. In the United States, the combination can be used on adults and children above from 12 years old, including in the elderly and in people with chronic medical conditions, but it does not apply to patients already hospitalized or who need oxygen.
Renato Kfouri warns, however, that the drug is not suitable for early treatment and that it needs to be recommended by a doctor. “A lot of people think that in a little while they want to buy these medications and use them at home. Make the diagnosis, take corticosteroids, antibiotics, dewormer. These treatments do not exist. The recommendation remains, there is no medication that works to prevent the disease, nor in the mild forms. Early treatment does nothing. ” Last month, Anvisa approved the use of Remdesivir, by the pharmaceutical Gilead, against Covid-19 – the first registration for a drug with use indicated in package inserts to treat the disease.
* With information from reporter Beatriz Manfredini
Get the latest news delivered to your inbox
Follow us on social media networks